Curcumin analog GO-Y030 inhibits tumor metastasis and glycolysis

J Biochem. 2023 Nov 30;174(6):511-518. doi: 10.1093/jb/mvad066.

Abstract

Tumor metastasis is one of the worst prognostic features of cancer. Although metastasis is a major cause of cancer-related deaths, an effective treatment has not yet been established. Here, we explore the antitumor effects of GO-Y030, a curcumin analog, via various mechanisms using a mouse model. GO-Y030 treatment of B16-F10 melanoma cells inhibited TGF-β expression and glycolysis. The invasion assay results showed almost complete invasion inhibition following GO-Y030 treatment. Mouse experiments demonstrated that GO-Y030 administration inhibited lung tumor metastasis without affecting vascular endothelial cells. Consistent with this result, GO-Y030 treatment led to the downregulation of MMP2 and VEGFα, inhibiting tumor invasion and metastasis. The silencing of eIF4B, a downstream molecule of S6, attenuated MMP2 expression. Our study demonstrates the novel efficacy of GO-Y030 in inhibiting tumor metastasis by regulating metastasis-associated gene expression via inhibiting dual access, glycolytic and TGF-β pathways.

Keywords: curcumin analog; matrix metallopeptidase 2; migration assay; scratching assay; tumor metastasis.

MeSH terms

  • Cell Line, Tumor
  • Curcumin* / pharmacology
  • Endothelial Cells
  • Humans
  • Matrix Metalloproteinase 2
  • Neoplasm Metastasis
  • Neoplasms*
  • Transforming Growth Factor beta

Substances

  • Curcumin
  • 1,5-bis(3,5-bis(methoxymethoxy)phenyl)penta-1,4-dien-3-one
  • Matrix Metalloproteinase 2
  • Transforming Growth Factor beta